Biogen Idec Inc (BIIB) 290.75 $BIIB
Is InterMune Inc. Your Next Biotech Buyout?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon May 19, 8:45PM CDT
InterMune was health care's top performing stock, thanks to positive phase 3 trial results for its lead drug Esbriet in idiopathic pulmonary fibrosis. Shares popped nearly 15% as Esbriet compared favorably with a competing drug also in late-stage...
Academic and Pharmaceutical Leaders Meet at the ALS Therapy Development Institute to Discuss Biomarkers in ALS
PRWeb - Mon May 19, 8:13AM CDT
The ALS Therapy Development Institute (ALS TDI) announced today that it is hosting a meeting on-site with leaders in academia and Pharma to discuss biomarkers in ALS. The meeting, held in collaboration with The ALS Association (ALSA), brings together 24 leaders from various academic institutions and pharmaceutical companies, including Genentech, Pfizer, Astra Zeneca, Biogen Idec, Bristol-Myers Squibb, Iron Horse Diagnostics, Inc., University of Massachusetts Medical School, Massachusetts General Hospital, SUNY Upstate Medical University, Barrow Neurological Institute, Voyager Therapeutics, The Michael J. Fox Foundation for Parkinson's Research, Weiner Laboratory, Northeast ALS Consortium, National Institute of Neurological Disorders and Stroke (NINDS), ALSA and ALS TDI.
Semi-Annual Changes to the NASDAQ OMX CRD Global Sustainability Index
GlobeNewswire - Mon May 19, 7:05AM CDT
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ), and CRD Analytics today announced the results of the semi-annual re-ranking of the NASDAQ OMX CRD Global Sustainability Index (Nasdaq:QCRD), which will become effective prior to market open on Monday, May 19, 2014.
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - Sat May 17, 9:51AM CDT
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S....
Why the Market Is Wrong About This Popular Marijuana Stock
Todd Campbell, The Motley Fool - Motley Fool - Sat May 17, 9:00AM CDT
Few areas of disease treatment have captured investors' attention as fully as medical marijuana has this year. While medical marijuana dispensaries have grabbed the spotlight lately, there are also biotechs attempting to create life-enhancing...
Drug-Pricing Rhetoric: Should Investors be Worried?
Brian Orelli, The Motley Fool - Motley Fool - Fri May 16, 8:30AM CDT
The drug-pricing story just won't go away. Bloomberg had a long article about the price of drugs claiming that there might be a drug that cost $1 million annually shortly. The pricing issue has previously been limited to orphan drug indications,...
Upcoming Conferences, Stock Price Movements and Support to Humanitarian Programs - Analyst Notes on Celgene, Biogen Idec, Incyte, Jazz Pharmaceuticals and Medivation
PR Newswire - Fri May 16, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Biogen Idec Inc. (NASDAQ: BIIB), Incyte Corporation (NASDAQ: INCY), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Medivation Inc. (NASDAQ: MDVN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2548-100free.
Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie
PR Newswire - Wed May 14, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Bristol-Myers Squibb Company (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2434-100free.
Is Isis Pharmaceuticals, Inc. Now a Bargain?
George Budwell, The Motley Fool - Motley Fool - Tue May 13, 11:31AM CDT
Isis Pharmaceuticals has one heck of a bad year in terms of the performance of its share price, falling close to 40% year-to-date. And starting in late February, the stock has essentially made a beeline lower. Given the dramatic and rapid nature of...
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 4.85% Gain
Comtex SmarTrend(R) - Mon May 12, 3:59PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $288.01 to a high of $301.00. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high of $291.28 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Cisco Powers Up as Dow Races to Hundred-Point Gain
Dan Carroll, The Motley Fool - Motley Fool - Mon May 12, 1:35PM CDT
Stocks have raced higher to start the new week, with the Dow Jones Industrial Average jumping out of the starting gate at the bell and rising 110 points as of 2:30 p.m. EDT. Most blue-chip stocks on the index are in the green. Tech giant Cisco ...
Technical Coverage on Biotech Stocks -- Research on Athersys, Lexicon Pharma, Biogen Idec, and Theravance
PR Newswire - Mon May 12, 11:30AM CDT
On Friday, May 09, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, and the index has advanced 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Athersys Inc. (NASDAQ: ATHX), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Biogen Idec Inc. (NASDAQ: BIIB) and Theravance Inc. (NASDAQ: THRX). Free technical research on ATHX, LXRX, BIIB and THRX can be downloaded upon signing up at:
Post Earnings Update: Biogen Idec Has Sunk 6.6% Lower in Past 2 Weeks (BIIB)
Comtex SmarTrend(R) - Mon May 12, 10:58AM CDT
When Biogen Idec (NASDAQ:BIIB) reported earnings 19 days ago on April 23rd, 2014, analysts, on average, expected the company to report earnings of $2.56 on sales of $2.0 billion. The company actually reported EPS of $2.47 on sales of $2.1 billion, missing EPS estimates by $0.08 and beating revenue estimates by $126.2 million. Shares of Biogen Idec have slipped from $306.75 to $286.65, representing a loss of 6.6%, since the company reported earnings 19 days ago.
Visualizing Biotech P/E Compression and Why It's a Buy Signal
at The Street - Mon May 12, 9:19AM CDT
J.P. Morgan analyst Geoff Meacham issued a cautiously optimistic note about the biotech sector this morning. While investor sentiment remains "fragile," and volatility continues to be high, Meacham believes the worst of the selling is over.
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
Richard A. Rudick Joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine
Business Wire - Mon May 12, 6:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine.
Biogen Idec and Sobi to donate 1 billion international units of clotting factor to support treatment of haemophilia in developing world
Thomson Reuters ONE - Mon May 12, 1:19AM CDT
- World Federation of Hemophilia Humanitarian Aid Program to Receive 500 Million International Units Over 5 Years -
Biogen Idec and Sobi to Donate 1 Billion International Units of Clotting Factor to Support Treatment of Hemophilia in Developing World
Business Wire - Mon May 12, 1:00AM CDT
Biogen Idec (NASDAQ:BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) today announced their intent to produce one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in the developing world at the World Federation of Hemophilia (WFH) 2014 World Congress. Initially, the companies have committed to donating up to 500 million IUs to the World Federation of Hemophilia over five years to support its efforts to raise the standard of care for people with hemophilia in the developing world. The remaining 5000 million IUs of clotting factor will be made available for future distribution.
Is InterMune Inc. Your Next Biotech Buyout?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon May 19, 8:45PM CDT
InterMune was health care's top performing stock, thanks to positive phase 3 trial results for its lead drug Esbriet in idiopathic pulmonary fibrosis. Shares popped nearly 15% as Esbriet compared favorably with a competing drug also in late-stage...
Academic and Pharmaceutical Leaders Meet at the ALS Therapy Development Institute to Discuss Biomarkers in ALS
PRWeb - Mon May 19, 8:13AM CDT
The ALS Therapy Development Institute (ALS TDI) announced today that it is hosting a meeting on-site with leaders in academia and Pharma to discuss biomarkers in ALS. The meeting, held in collaboration with The ALS Association (ALSA), brings together 24 leaders from various academic institutions and pharmaceutical companies, including Genentech, Pfizer, Astra Zeneca, Biogen Idec, Bristol-Myers Squibb, Iron Horse Diagnostics, Inc., University of Massachusetts Medical School, Massachusetts General Hospital, SUNY Upstate Medical University, Barrow Neurological Institute, Voyager Therapeutics, The Michael J. Fox Foundation for Parkinson's Research, Weiner Laboratory, Northeast ALS Consortium, National Institute of Neurological Disorders and Stroke (NINDS), ALSA and ALS TDI.
Semi-Annual Changes to the NASDAQ OMX CRD Global Sustainability Index
GlobeNewswire - Mon May 19, 7:05AM CDT
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ), and CRD Analytics today announced the results of the semi-annual re-ranking of the NASDAQ OMX CRD Global Sustainability Index (Nasdaq:QCRD), which will become effective prior to market open on Monday, May 19, 2014.
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - Sat May 17, 9:51AM CDT
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S....
Why the Market Is Wrong About This Popular Marijuana Stock
Todd Campbell, The Motley Fool - Motley Fool - Sat May 17, 9:00AM CDT
Few areas of disease treatment have captured investors' attention as fully as medical marijuana has this year. While medical marijuana dispensaries have grabbed the spotlight lately, there are also biotechs attempting to create life-enhancing...
Drug-Pricing Rhetoric: Should Investors be Worried?
Brian Orelli, The Motley Fool - Motley Fool - Fri May 16, 8:30AM CDT
The drug-pricing story just won't go away. Bloomberg had a long article about the price of drugs claiming that there might be a drug that cost $1 million annually shortly. The pricing issue has previously been limited to orphan drug indications,...
Upcoming Conferences, Stock Price Movements and Support to Humanitarian Programs - Analyst Notes on Celgene, Biogen Idec, Incyte, Jazz Pharmaceuticals and Medivation
PR Newswire - Fri May 16, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Biogen Idec Inc. (NASDAQ: BIIB), Incyte Corporation (NASDAQ: INCY), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Medivation Inc. (NASDAQ: MDVN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2548-100free.
Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie
PR Newswire - Wed May 14, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Bristol-Myers Squibb Company (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2434-100free.
Is Isis Pharmaceuticals, Inc. Now a Bargain?
George Budwell, The Motley Fool - Motley Fool - Tue May 13, 11:31AM CDT
Isis Pharmaceuticals has one heck of a bad year in terms of the performance of its share price, falling close to 40% year-to-date. And starting in late February, the stock has essentially made a beeline lower. Given the dramatic and rapid nature of...
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 4.85% Gain
Comtex SmarTrend(R) - Mon May 12, 3:59PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $288.01 to a high of $301.00. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high of $291.28 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Cisco Powers Up as Dow Races to Hundred-Point Gain
Dan Carroll, The Motley Fool - Motley Fool - Mon May 12, 1:35PM CDT
Stocks have raced higher to start the new week, with the Dow Jones Industrial Average jumping out of the starting gate at the bell and rising 110 points as of 2:30 p.m. EDT. Most blue-chip stocks on the index are in the green. Tech giant Cisco ...
Technical Coverage on Biotech Stocks -- Research on Athersys, Lexicon Pharma, Biogen Idec, and Theravance
PR Newswire - Mon May 12, 11:30AM CDT
On Friday, May 09, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, and the index has advanced 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Athersys Inc. (NASDAQ: ATHX), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Biogen Idec Inc. (NASDAQ: BIIB) and Theravance Inc. (NASDAQ: THRX). Free technical research on ATHX, LXRX, BIIB and THRX can be downloaded upon signing up at:
Post Earnings Update: Biogen Idec Has Sunk 6.6% Lower in Past 2 Weeks (BIIB)
Comtex SmarTrend(R) - Mon May 12, 10:58AM CDT
When Biogen Idec (NASDAQ:BIIB) reported earnings 19 days ago on April 23rd, 2014, analysts, on average, expected the company to report earnings of $2.56 on sales of $2.0 billion. The company actually reported EPS of $2.47 on sales of $2.1 billion, missing EPS estimates by $0.08 and beating revenue estimates by $126.2 million. Shares of Biogen Idec have slipped from $306.75 to $286.65, representing a loss of 6.6%, since the company reported earnings 19 days ago.
Visualizing Biotech P/E Compression and Why It's a Buy Signal
at The Street - Mon May 12, 9:19AM CDT
J.P. Morgan analyst Geoff Meacham issued a cautiously optimistic note about the biotech sector this morning. While investor sentiment remains "fragile," and volatility continues to be high, Meacham believes the worst of the selling is over.
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
Richard A. Rudick Joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine
Business Wire - Mon May 12, 6:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine.
Biogen Idec and Sobi to donate 1 billion international units of clotting factor to support treatment of haemophilia in developing world
Thomson Reuters ONE - Mon May 12, 1:19AM CDT
- World Federation of Hemophilia Humanitarian Aid Program to Receive 500 Million International Units Over 5 Years -
Biogen Idec and Sobi to Donate 1 Billion International Units of Clotting Factor to Support Treatment of Hemophilia in Developing World
Business Wire - Mon May 12, 1:00AM CDT
Biogen Idec (NASDAQ:BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) today announced their intent to produce one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in the developing world at the World Federation of Hemophilia (WFH) 2014 World Congress. Initially, the companies have committed to donating up to 500 million IUs to the World Federation of Hemophilia over five years to support its efforts to raise the standard of care for people with hemophilia in the developing world. The remaining 5000 million IUs of clotting factor will be made available for future distribution.
